No-carrier-added radiosynthesis of [123I]HIPDM: N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-[123I]iodobenzyl)-1,3-propanediamine
✍ Scribed by S.M. Moerlein; G.S. Lannoye; M.J. Welch
- Book ID
- 103922475
- Publisher
- Elsevier Science
- Year
- 1990
- Weight
- 444 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0883-2889
No coin nor oath required. For personal study only.
✦ Synopsis
The multi-millicurie production of the SPECT radiopharmaceutical N,N,N'-trimethyl-N'-(2-hydroxy-3-methyl-5-[123I] iodobenzyl)-1,3-propanediamine [( 123I]HIPDM) in high specific activity is described. Using no-carrier-added electrophilic iododeprotonation reactions and HPLC purification, [123I]HIPDM can be isolated in 70-76% radiochemical yield and specific activity greater than 2000 Ci/mmol within an overal preparation time of 75 min. This methodology is readily adapted to the clinical setting, and eliminates the need for co-injection of macroscopic HIPDM in SPECT imaging procedures.
📜 SIMILAR VOLUMES
## Abstract The radiosynthesis of a novel tropane derivative [^123^I]KUC‐25019, [[^123^I];__N__‐(3‐iodoprop‐(2__E__)‐enyl)‐2α‐(imino‐methyl)‐3β‐(3′,4′‐dichlorophenyl)nortropane], a potential inhibitor of the dopamine transporter is reported. The synthetic routes include the preparation of standard